Yann Poulouin

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial”.

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(22)00043-2

N/A

1.5DataRank · unranked

37 citations

Philippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Terrence Chua +11 more

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Journal of the American Heart Association(2023)10.1161/jaha.122.029216

N/A

1.1DataRank · unranked

40 citations

Philippe Gabríel Steg, Yann Poulouin, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +10 more

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

The American Journal of Medicine(2022)10.1016/j.amjmed.2022.02.016

N/A

0.401DataRank · unranked

5 citations

Patrícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera Bittner, Andrzej Budaj +13 more

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

European Heart Journal - Cardiovascular Pharmacotherapy(2024)10.1093/ehjcvp/pvae025

N/A

0DataRank · unranked

24 citations

Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +82 more